Abnova and Japan National Cancer Center Research Institute Present Pancreatic Cancer Biomarker Findings at 8th JHUPO Conference

Neihu, Taiwan (April 2, 2010).throughput monoclonal antibody production. Japan
Abnova and Japan National Cancer Center ResearchNational Cancer Center is a distinguished center of
Institute will be presenting the result of theexcellence for research and treatment of cancer
pancreatic cancer biomarker findings at the upcomingpatients. Leveraging Abnova's large collection of
8th Japan Human Proteome Organization (JHUPO)monoclonal antibodies and National Cancer Center's
conference on July 26-27, 2010 in Tokyo, Japan. Thiswell-maintained archive of human samples and clinical
is the culmination of more than one and half years ofrecords, two parties joint force to apply more than
research discovery and validation work utilizingone thousand monoclonal antibodies to pathological
antibody-based tissue microarray profiling to identifyspecimens and compared protein expression profiles
novel protein biomarkers which are preferentiallyof pancreatic cancer versus normal patients. Relevant
expressed on cancer tissue followed by confirmationprotein biomarkers are then evaluated for their
of the same proteins released into the blood stream.presence in sera by sandwich ELISA technique for
These biomarkers are benchmarked against thequantitative analysis. Protein levels are also compared
current standard biomarker, CA-19.9 for pancreaticto the levels of normal individuals for evaluation and
cancer. The newly discovered biomarkers hold greatverification of statistical significance. For the most
value for early detection, diagnostic, prognostic, andpart, the antibody screening and tissue section
theranostic applications in the management andstaining can be automated. However,
treatment of pancreatic patients. Abnova has theimmunohistochemical interpretation and subsequent
exclusive right in the commercialization of the derivedserum validation work have taken more time.
biomarkers and National Cancer Center ResearchThe study will demonstrate the utility and collective
Institute will receive royalty from sales of commercialpower of large-scale monoclonal antibody screening
products.and protein expression profiling. The discovered
Human tissue and sera are the two main sources ofbiomarkers will challenge us on our understanding of
clinical sample available to clinicians and researcherspancreatic cancer and reinforce the complexity of
for investigation of biomarkers which have gainedbiology and disease process. Such high throughput,
increased importance in new era of personalizedantibody screening platform can be readily applied to
medicine. The approach undertook by Abnova andall the major cancers for biomarker discovery and
Japan National Cancer Center for the discovery ofvalidation. It is an invaluable system for translational
pancreatic cancer biomarkers is unprecedented.research and new diagnostic and therapeutic
Abnova is a biotech company specializing in highdevelopments.